NASDAQ:ALLO

Allogene Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy ALLO

*Your capital is at risk

$2.00

-0.0500 (-2.44%)

At Close: Jun 03, 2026

Allogene Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 42.16. In total, the insiders bought 19.78M and sold 730.17K ALLO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	42.16
● Buy	19.78M shares
● Sell	730.17K shares
66% Buy Activity Moderate Positive Correlation
Sell Signal Low Confidence Mar 16, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 42.16. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 03, 2025 Sell	Common Stock S-Sale	Moore Timothy L. Chief Technical Officer	Officer	14 746 Value: $25.2K
Feb 03, 2025 Sell	Common Stock S-Sale	Parker Geoffrey M. Chief Financial Officer	C-Suite Officer	4 361 Value: $8K
Feb 03, 2025 Sell	Common Stock S-Sale	Douglas Earl Martin SVP, General Counsel	Officer	6 404 Value: $11.0K
Jan 24, 2025 Buy	Common Stock A-Award	Douglas Earl Martin SVP, General Counsel	Officer	144 928 Value: $281.2K
Jan 24, 2025 Buy	Stock Option (Right to buy) A-Award	Douglas Earl Martin SVP, General Counsel	Officer	512 370 Value: $994.0K
Jan 24, 2025 Buy	Common Stock A-Award	Parker Geoffrey M. Chief Financial Officer	C-Suite Officer	173 913 Value: $337.4K
Jan 24, 2025 Buy	Stock Option (Right to buy) A-Award	Parker Geoffrey M. Chief Financial Officer	C-Suite Officer	614 844 Value: $1.19M
Jan 24, 2025 Buy	Common Stock A-Award	Yoshiyama Annie SVP, Finance	Officer	36 232 Value: $70.3K
Jan 24, 2025 Buy	Stock Option (Right to buy) A-Award	Yoshiyama Annie SVP, Finance	Officer	128 093 Value: $248.5K
Jan 24, 2025 Buy	Common Stock A-Award	Roberts Zachary EVP Of R&d	Officer	173 913 Value: $337.4K
Jan 24, 2025 Buy	Stock Option (Right to buy) A-Award	Roberts Zachary EVP Of R&d	Officer	614 844 Value: $1.19M
Jan 24, 2025 Buy	Common Stock A-Award	Belldegrun Arie Director	Director	369 957 Value: $717.7K
Jan 24, 2025 Buy	Stock Option (Right to buy) A-Award	Belldegrun Arie Director	Director	1 307 927 Value: $2.54M
Jan 24, 2025 Buy	Common Stock A-Award	Chang David D President And CEO	CEO / President	552 174 Value: $1.07M
Jan 24, 2025 Buy	Stock Option (Right to buy) A-Award	Chang David D President And CEO	CEO / President	1 952 130 Value: $3.79M
Jan 24, 2025 Buy	Stock Option (Right to buy) A-Award	Chang David D President And CEO	CEO / President	1 952 130 Value: $3.79M
Jan 24, 2025 Buy	Common Stock A-Award	Chang David D President And CEO	CEO / President	552 174 Value: $1.07M
Jan 24, 2025 Buy	Common Stock A-Award	Belldegrun Arie Director	Director	369 957 Value: $717.7K
Jan 24, 2025 Buy	Stock Option (Right to buy) A-Award	Roberts Zachary EVP Of R&d	Officer	614 844 Value: $1.19M
Jan 24, 2025 Buy	Common Stock A-Award	Roberts Zachary EVP Of R&d	Officer	173 913 Value: $337.4K
Jan 24, 2025 Buy	Stock Option (Right to buy) A-Award	Yoshiyama Annie SVP, Finance	Officer	128 093 Value: $248.5K
Jan 24, 2025 Buy	Common Stock A-Award	Yoshiyama Annie SVP, Finance	Officer	36 232 Value: $70.3K
Jan 24, 2025 Buy	Stock Option (Right to buy) A-Award	Parker Geoffrey M. Chief Financial Officer	C-Suite Officer	614 844 Value: $1.19M
Jan 24, 2025 Buy	Common Stock A-Award	Parker Geoffrey M. Chief Financial Officer	C-Suite Officer	173 913 Value: $337.4K
Jan 24, 2025 Buy	Stock Option (Right to buy) A-Award	Douglas Earl Martin SVP, General Counsel	Officer	512 370 Value: $994.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ALLOGENE THERAPEUTICS INC.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic ...

Read Full Profile Here